Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13)

Author： Harter Philipp   Sehouli Jalid   Kimmig Rainer   Rau Jörn   Hilpert Felix   Kurzeder Christian   Elser Gabriele   Bois Andreas  

Publisher： Springer Publishing Company

ISSN： 0167-6997

Source： Investigational New Drugs, Vol.31, Iss.6, 2013-12, pp. : 1499-1504

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase I study of non-pegylated liposomal doxorubicin in combination with ifosfamide in adult patients with metastatic soft tissue sarcomas

By Stroppa Elisa   Bertuzzi Alexia   Comite Gabriele   Mussi Chiara   Lutman Romano   Barbato Alfredo   Santoro Armando  

Investigational New Drugs, Vol. 28, Iss. 6, 2010-12 ,pp. : 834-838

Springer Publishing Company

Access to resources Recommend Favorite

Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx®) in combination with topotecan in patients with advanced malignancies

By Ghesquières Hervé   Faivre Sandrine   Djafari Latifa   Pautier Patricia   Lhommé Catherine   Lozahic Stéphanie   Djazouli Kamel   Armand Jean-Pierre   Raymond Eric  

Investigational New Drugs, Vol. 24, Iss. 5, 2006-09 ,pp. : 413-421

Springer Publishing Company

Access to resources Recommend Favorite

Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study

By Boér Katalin  

Investigational New Drugs, Vol. 30, Iss. 2, 2012-04 ,pp. : 681-687

Springer Publishing Company

Access to resources Recommend Favorite

A phase II, open label, monotherapy study of liposomal doxorubicin in patients with metastatic malignant melanoma

By Smylie Michael   Wong Ralph   Mihalcioiu Catalin   Lee Chris   Pouliot Jean-Francois  

Investigational New Drugs, Vol. 25, Iss. 2, 2007-04 ,pp. : 155-159

Springer Publishing Company

Access to resources Recommend Favorite

Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors

By El-Rayes Basil F.   Ibrahim Dina   Shields Anthony F.   LoRusso Patricia M.   Zalupski Mark M.   Philip Philip A.  

Investigational New Drugs, Vol. 23, Iss. 1, 2005-01 ,pp. : 57-62

Springer Publishing Company

Access to resources Recommend Favorite